346 results about "Neuralgia" patented technology

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

A traditional Chinese medicine for treating facial paralysis, facial spasm, trigeminal neuralgia prepared from preserved batryticated silkworm powder 60-120g, buthus martensi kirsch powder 40-80g, giant typhonium tuber powder 55-110g, Chinese angelica root powder 58-115g, milk vetch root powder 60-120g, rhizome of Sichuan lovage powder 50-100g, white mustard seed powder 10-50g, ledebouriella root powder 60-120g, dahurian angelica root powder 64-110g, rhizoma Gastrodiae powder 75g, notopterygium root powder 55-95g, and licorice powder 15-40g.

The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

A medicament which contains a urea derivative or a salt thereof as an active ingredient is disclosed. The medicament has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and / or inflammatory disorders.

The invention discloses a bioengineering lacquer putty as well as preparation method and use thereof. The bioengineering lacquer putty comprises: talcum powder, heavy calcium carbonate, emiaste, hydroxypropylmethylcellulose, adhesive, calcium stearate, tourmaline powder and bergmeal. the bioengineering lacquer putty of the invention has the sterilizing and deodorizing function, can automatically remove the harmful gas such as methyl aldehyde and the like, has no pollution, and ensure the safety of the human body and the animals and plants. The bioengineering lacquer putty of the invention has higher production amount of the negative ion and far infrared emissing ability, can prevent the electromagnetic radiation, can rapidly absorb and remove the abnormal flavour generated by the paint, the colloid and the like, absorb the smoke flavor for a long time, and has definite treating efficacy for the limbs ice-cold disease, shoulder pain, lumbago, physical pain, neuralgia and the like.

The invention discloses a sacral nerve stimulation system, which comprises an implanted nerve stimulator, a stimulator programmed controller and a stimulating electrode, wherein the implanted nerve stimulator comprises a MCU (micro-programmed control unit) control module, a special chip, a protection circuit module, a power management module and a radio frequency communication module; the stimulator programmed controller comprises an ARM control module, a USB communication module, a charger module, a medical implanted equipment special communication module, a storage module, a display module and a key module; the stimulating electrode is connected to the special chip; and sacral nerves are directly stimulated after a stimulating pulse is received. The implant stimulator disclosed by the invention, by generating lasting electric pulse, can conduct electric stimulation on target nerves in a plurality of parts; the implant stimulator is controlled by the stimulator programmed controller in vitro; and the stimulation system achieves a satisfying effect when applied to such fields as uracratia, urinary retention, Parkinson, spinal neuralgia, peripheral electrical stimulation therapy and the like.

A Chinese medicine for treating neuralgia, vascular headache, cerebral ischemia and cerebral apoplexy sequelae is prepared from 41 Chinese-medicinal materials including ginseng, astragalus root, Chinese angelica root, white peony root, etc.

A pharmaceutical composition comprising: (a) meloxicam or a pharmaceutically acceptable salt thereof; and (b) one or more additional pharmaceutically active compounds selected from antacids, sedatives, and central nervous system stimulants, and the use of such composition of an inflammatory disease, symptoms of an inflammatory disease, including various symptoms thereof, and / or headache, toothache, ache after tooth extraction, sore throat, otalgia, arthralgia, neuralgia, lumbago, myalgia, muscle stiffness of shoulder, pain of contusion, pain of fracture, pain of sprain, menstrual pain, traumatic pain, chill, exothermic reaction and / or cold and various symptoms of cold such as sore throat, chill, pyrexia, headache, arthralgia and muscle pain.

A Chinese medicine in the form of adhesive plaster for treating the pain of neck, shoulder, lumbus and leg, arthritis, and neuralgia is prepared from more than 50 Chinese-medicinal materials including notoginseng, wild aconite root, centipede, Chinese angelica root, etc through decocting matrix, preparing ointment, pulverizing, proportional mixing, and spreading. Its advantage is high effective rate up to more than 97%.

A medicine for resisting rheumatism and alleviating pain is made from the materials with the following weight portions: 50 to 55 portions of gentian root, 70 to 75 portions of hemlock parsley, 70 to 75 portions of peach kernel, 65 to 70 portions of safflower, 50 to 60 portions of liquorice, 45 to 50 portions of notopterygium root, 60 to 65 portions of myrrh, 70 to 75 portions of angelica, 70 to 75 portions of boninrousette, 45 to 50 portions of nutgrass galingale rhizome, 75 to 80 portions of achyranthes root, 65 to 70 portions of earthworm, 65 to 70 portions of rhizoma atractylodis, 55 to 60 portions of corktree bark, 60 to 70 portions of milk veteh, 60 to 65 portions of salvia miltiorrhiza, 60 to 65 portions of spatholobus stem, 60 to 65 portions of pawpaw, 55 to 65 portions of paniculater swallowwort root, 60 to 65 portions of pachyma cocos, 55 to 60 portions of ground beetle, 40 to 45 portions of natural copper and 35 to 40 portions of dragon blood. The medicine can cure rheumatoid arthritis, hyperosteogeny, sciatica, cervical spondylosis, periarthritis, various arthralgia, neuralgia, kidney deficiency, lumbocrural pain, myalgia, exercise injury pain and lumbar disc protrusion, which is effective in treatment.

New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium chlorite) and / or spirulina. The medicaments provide high metabolic activities and sustain those activities over prolonged periods of time, thus being useful for treating a large variety of ailments, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.

The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and / or treat acute and chronic pain developed as a consequence of surgery, especially superficial and / or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

This invention refers to the pharmaceutical combinations of Ketorolac salts and B-complex; to the methods used to make said combinations; and particularly, to ketorolac and B-complex synergic combinations useful in the treatment of patients that suffer from moderate to severe pain and neuralgias in different body sites.

The invention relates to 4- amino piperidines compound showed in general formula 1, its optic antimer, racemic material, or its medicinal salt, and medical compound containing them. The invention also relates to the application in preparing drug preventing or treating pain after operation, cephalagra, visceralgia, neuralgia and addiction and survivability caused by analgesic such as opium drug.

A capsule or instant particles of sturgeon chondroitin for treating cardiovascular diseases, neuralgia, arthritis and hepatitis and preventing cancers is prepared from the head bone and cartilage of sturgeon through preteating, mashing, adding alkali and enzyme, dual degradating, filter, depositing in alcohol, pressure filter, baking, pulverizing to obtain chondroitin, and loading in capsules or shaping.

This invention relates to urea derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and / or inflammatory disorders.

The invention belongs to the fields of biochemistry and molecular biology, relates to a new conopeptide, and a medicinal composition, a preparation method and uses thereof, also relates to a nucleic acid construct, an expression vector of the nucleic acid construct, a converted cell of the expression vector and a fusion protein of the conopeptide, and further relates to a method for blocking out an acetylcholine receptor, and pharmaceutical uses of the conopeptide. The new conopeptide K41JM and analogs thereof can specifically block out the acetylcholine receptor (nAChRs) (such as alpha9alpha10nAChR), have can treat neuralgia, cancer chemotherapy, breast cancer, lung cancer, wound healing, encephalomyelitis, epilepsy and ischaemia, and have good application prospects in the preparation of pain easing medicines, anticancer medicines and neuroscience tool medicines.

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on both the 2- and 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and / or GABAA receptors.

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1 )antagonist; and a pharmaceuticalcomposition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

The present invention relates to one kind of medicine for treating rheumatic diseases, and the medicine is honeyed bolus prepared with aconite root, wild aconite root, speranskia herb, cassia twig, scorpion and other 15 kinds of Chinese medicinal materials in certain weight proportion. The medicine is used mainly for treating rheumatic pain, arthralgia, neuralgia, hyperosteogeny, protrusion of lumbar intervertebral disc, etc caused by wind, cold, dampness and heat. Clinical application for years proves its high curative rate and effectiveness.

Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like.wherein Q represents ethylene, etc., R1, R2 and R3 represent hydrogen, etc., X1 represents C1-6 alkylene, etc., X2 represents C1-6 alkylene, etc., A1 represents a 5- to 6-membered heterocyclic group, etc., and A2 represents C6-14 aryl, etc.

The invention provides an anti-inflammatory and pain-killing medical composition; chondroitin sulfate and a non-steroidal anti-inflammatory agent are used as active ingredients and mixed with a medical carrier to form the composition. Non-steroidal anti-inflammatory agent includes but not confines in diclofenac sodium (potassium), naprosyn and Lornoxicam; the composition exists in forms of squirt, freeze-dried powder and large-capacity transfusion for intravenous medication of a human body. The composition can be applied to symptomatic treatments of various febrile illnesses, various arthritises and inflammatory rheumatic diseases, soft tissue rheumatisms, neuralgia, arthralgia and pains, wounds relevant to degenerative diseases of spines, or postoperative pains.

A compound beetoxin injection for treating neuralgia, periomethritis, rheumatic and rheumatoid arthritis, allergic dermatopathy, allergic rhinitis, etc and its preparing process are disclosed. Its advantages include correct dosage, high curative effect and high safety.

An interior-applied Chinese medicine for treating trigeminal neuraliga is prepared from 10 Chinese-medicinal materials including Chuan-xiong rhizome, gastrodia tuber, scorpion, earthworm, etc.

The present invention provides the GST fusion expression and application of a kind of conotoxin MVII A gene. GST-CTX MVII A recombinant fusion protein is cloned and expressed in colibacillus, and through GST affinity chromatography purified GST-CTX MVII A fusion protein is obtained. The fusion protein the present invention obtains may be applied in preparing medicine for treating intractable painof cancer and AIDS patient in the late stage, preparing analgesic for treating post-operation acute pain, pain of burn, biliary colic, intractable neuralgia, etc., and preparing medicine with nerve protecting function for treating cerebral ischemia and cerebral damage. The obtained fusion protein has relatively great molecular weight and relatively long half life in body and may be enzyme incisedto obtain active omiga-conotoxin MVII A small peptide for direct medicine development.

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

The invention belongs to the technical field of medical instruments, relates to a physical therapy stand and in particular relates to a prosopalgia physical therapy stand which comprises a support rack, wherein a shell is arranged on the support rack; a head holding zone is arranged on the shell; adjusting devices are arranged on the shell; a pair of physical therapy fixing devices corresponding to the head holding zone are arranged on the adjusting devices; the adjusting devices comprise power structures; the output ends of the power structures are connected with rough adjusting structures matched with the pair of the physical therapy fixing devices; fine adjusting structures matched with the physical therapy fixing devices are connected with the rough adjusting structures; the power structures comprise transmission boxes fixedly connected with the shell; driving wheels are rotationally connected in the transmission boxes; driven wheels are meshed with the driving wheels; the driven wheels are coaxially connected with positive rotating components connected with the rough adjusting structures; and the driven wheels are also coaxially connected with negative rotating components connected with the fine adjusting structures. By adopting the physical therapy stand, the problem that a fixing device of a conventional physical therapy stand is inconvenient to use can be effectively solved.